Author Question: A client is beginning aldesleukin (Proleukin) therapy for advanced renal carcinoma. The nurse should ... (Read 144 times)

cdr_15

  • Hero Member
  • *****
  • Posts: 546
A client is beginning aldesleukin (Proleukin) therapy for advanced renal carcinoma. The nurse should monitor the client for:
 
  1. capillary leak syndrome.
  2. hypertension.
  3. hyperglycemia.
  4. hyperuricemia.

Question 2

What is the expected outcome for the client receiving filgrastim (Neupogen)?
 
  1. Increased white cell count
  2. Reduction in tumor size
  3. Reduction in paresthesia
  4. Increased platelet count



billybob123

  • Sr. Member
  • ****
  • Posts: 336
Answer to Question 1

Correct Answer: 1
Rationale 1: Capillary leak syndrome is a significant side effect of aldesleukin and can be fatal.
Rationale 2: Aldesleukin does not cause hypertension.
Rationale 3: Hyperglycemia is not a side effect of aldesleukin.
Rationale 4: Hyperuricemia is not a side effect of aldesleukin.
Global Rationale: Aldesleukin is a toxic drug that has the potential to cause serious adverse effects in virtually any organ system. Many of the adverse effects are caused by capillary leak syndrome, a serious condition in which plasma proteins and other substances leave the blood and enter the interstitial spaces because of porous capillaries. If not monitored carefully, capillary leak syndrome can result in death. The drug is not associated with hypertension, hyperglycemia, or hyperuricemia.

Answer to Question 2

Correct Answer: 1
Rationale 1: Filgrastim increases white cell counts.
Rationale 2: Filgrastim has no effect on tumor size.
Rationale 3: Filgrastim does not reduce paresthesia.
Rationale 4: Filgrastim has no effect on platelet counts.
Global Rationale: Filgastim is a colony-stimulating factor which stimulates the production of granulocytes. It has no effect on tumor size, does not reduce paresthesia, and has no effect on platelet counts.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question


 

Did you know?

According to the National Institute of Environmental Health Sciences, lung disease is the third leading killer in the United States, responsible for one in seven deaths. It is the leading cause of death among infants under the age of one year.

Did you know?

Immunoglobulin injections may give short-term protection against, or reduce severity of certain diseases. They help people who have an inherited problem making their own antibodies, or those who are having certain types of cancer treatments.

Did you know?

Medication errors are more common among seriously ill patients than with those with minor conditions.

Did you know?

In inpatient settings, adverse drug events account for an estimated one in three of all hospital adverse events. They affect approximately 2 million hospital stays every year, and prolong hospital stays by between one and five days.

Did you know?

The newest statin drug, rosuvastatin, has been called a superstatin because it appears to reduce LDL cholesterol to a greater degree than the other approved statin drugs.

For a complete list of videos, visit our video library